Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kairos Pharma Ltd KAPA

Healthcare Biotechnology
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that... see more

Recent & Breaking News (NYSEAM:KAPA)

Kairos Pharma Provides Shareholder Update

Business Wire 6 days ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Business Wire October 20, 2025

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Business Wire October 7, 2025

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Business Wire September 18, 2025

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Business Wire September 11, 2025

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Business Wire September 3, 2025

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Business Wire September 2, 2025

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Business Wire July 16, 2025

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Business Wire July 15, 2025

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Business Wire June 3, 2025

Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference

Newsfile May 6, 2025

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Business Wire April 28, 2025

Kairos Pharma Ltd. Provides Letter to Stockholders

Business Wire April 24, 2025

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Business Wire April 17, 2025

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Business Wire March 31, 2025

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Business Wire March 27, 2025

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Business Wire March 20, 2025

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Business Wire February 26, 2025

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Business Wire February 18, 2025

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Business Wire February 6, 2025